Comparative Pharmacology
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus CEFTAZIDIME IN DEXTROSE CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTAN IN PLASTIC CONTAINER versus CEFTAZIDIME IN DEXTROSE CONTAINER.
CEFOTAN IN PLASTIC CONTAINER vs CEFTAZIDIME IN DEXTROSE CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and cross-linking of peptidoglycan. It has broad-spectrum activity against gram-negative and gram-positive bacteria, including anaerobes, and is resistant to beta-lactamases.
Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition, leading to cell lysis and death.
1 to 2 g intravenously or intramuscularly every 12 hours for 5 to 10 days. Maximum dose 6 g daily.
1-2 g intravenously every 8 hours.
None Documented
None Documented
2.8-3.2 hours in normal renal function; prolonged to 12-30 hours in severe renal impairment (CrCl <10 mL/min).
1.9 hours (normal renal function); prolonged to 22-30 hours in ESRD
Primarily renal (76-85% unchanged in urine via glomerular filtration and tubular secretion); biliary excretion accounts for <10%, with small amounts in feces.
Renal: 80-90% unchanged drug via glomerular filtration; biliary: <1%; fecal: <1%
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic